GUJARAT THEMIS BIOSYN LIMITED

CIN: L24230GJ1981PLC004878
REGD. OFFICE &FACTORY: 69/C GIDC INDUSTRIAL ESTATE,
VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA
TEL: 0260-2430027 / 2400639
E-mail:hrm@gtbl.in.net

GTBL/BSE/NSE/2026-27/63

21st September 2026

To,

Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G
Bandra Kurla Complex
Bandra East, Mumbai 400051
Symbol: GUJTHEM

Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street
Mumbai 400001

Scrip Code: 506879

Dear Sir / Madam,

Subject: Corrigendum to the Notice of Annual General Meeting

Gujarat Themis Biosyn Limited (the Company) had sent the notice of 45th Annual General Meeting ("AGM") of Gujarat Themis Biosyn Limited, which was circulated to the Members on 4th September, 2026, convening the 45th AGM of the Company to be held on Wednesday, 30th September, 2026 at 12:30 p.m. (IST) at 69/A, GIDC Industrial Estate, Vapi-396195, Dist. Valsad, Gujarat

The Company, by way this corrigendum, wishes to amend Resolution No. 8 and its explanatory statement to align with applicable provisions of SEBI ICDR Regulations, for consideration and approval of the Members at the ensuing AGM. Consequent to this corrigendum, Resolution No. 8 and explanatory statement related thereto shall be read in conjunction with this corrigendum.

All other contents of the Annual General Meeting, save and except as modified or supplemented by the Corrigendum, shall remain unchanged.

This is for your information and record please.

Thanking you

Yours faithfully

For Gujarat Themis Biosyn Limited

VINEET GANESH GAWANKAR
Digitally signed by VINEET GANESH GAWANKAR
Date: 2026.09.21 20:52:51 +05'30'

Vineet Gawankar
Company Secretary & Compliance Officer

GUJARAT THEMIS BIOSYN LIMITED

CIN: L24230GJ1981PLC004878

REGD. OFFICE & FACTORY: 69/C GIDC INDUSTRIAL ESTATE, VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA https://www.gtbl.in/
TEL: 0260-2430027 / 2400639, E-mail: hrm@gtbl.in.net

1st Corrigendum to AGM Notice

Dear Members

Gujarat Themis Biosyn Limited (the Company) had sent the notice dated September 2, 2026 (AGM Notice or Notice) for annual general meeting scheduled to be held on Wednesday, September 30, 2026 at 12:30 pm, to the Members of the Company.

The Company, through this corrigendum, aims to inform the Members of the Company regarding certain amendments and clarifications (the Amendments) in the Resolution at Item no. 8 of the Notice for raising funds by issue of Equity Shares through Preferential Issue and explanatory statement relating thereto, in compliance with and to align with the applicable laws / SEBI ICDR Regulations.

Accordingly, the following Amendments are being made and shall form an integral part of the Notice.

1 In the Notice, page no. 3, in the first para of resolution no. 8, text relating to number of equity shares and amount is substituted by the following texts, due to change is price calculation.

“…up to 82,92,081 equity shares of face value of Rs. 1 each of the Company fully paid-up (the Equity Shares), at a price of Rs. 404 per equity share (the Issue Price), aggregating up to Rs. 335,00,00,724/-…”

2 In the Notice, page no. 3, in the first para of resolution no. 8, table containing details relating to the proposed allottees shall be substituted by the following table with updated details of the shares and amounts. There is no change in names of the proposed allottees.

No.	Name of the Investor or Proposed Allottee	No. of Equity shares to be allotted	Total amount to be paid, (In Rs)	Category
1	Pharmaceutical Business Group (India) Limited	61,88,121	250,00,00,884	Promoter Group
2	Yusuf Khwaja Hamied	2,47,526	10,00,00,504	Public
3	Special Situation India Fund	4,64,108	18,74,99,632	Public
4	India Special Assets Fund III	6,90,594	27,89,99,976	Public
5	ISAF III Onshore Fund	7,01,732	28,34,99,728	Public

3 In the Notice, page no. 14, in Sr. No. 1 (About the Issue), the amount is substituted by the amount as “Rs. 335,00,00,724”.

4 In the Notice, page no. 15, in Sr. No. 2 (Objects of the Issue and timeline), the table below first para is replaced with the following table with intent to make the object clause clearer and precise, without changing the objects.

Sr. No.	Objects for which fund to utilize	Amount to be utilised, Rs.	Timelines for utilization
1	Redemption of Non-convertible debenture (NCDs) and/or Repayment / prepayment of the borrowing and interest thereon availed / to be availed for payment of consideration and cost of acquisition of 100% equity stake in MicroBiopharm Japan Co., Ltd. (including by way of investment in the Company's subsidiary in Japan in form of capital contribution / loan).	310,00,00,724	12 months
2	General Corporate Purposes (not exceed 25%)*	25,00,00,000	12 months
	Total	335,00,00,724	

The para under the heading "Interim Use of Issue Proceeds" is replaced with the following para with intent to make it precise and in line with appliable guidelines.

"Pending complete utilization of the Issue Proceeds for the Objects described above, the Company intends to invest the Issue Proceeds in deposits in scheduled commercial banks, securities issued by government of India and/or creditworthy instruments as permitted under applicable laws / guidelines."

5 In the Notice, page no. 16, in Sr. No. 3 (Monitoring of utilization of funds), the existing texts is replaced with the following texts with name of the agency.

"India Rating and Research Private Limited, a SEBI registered agency, is appointed as the monitoring agency to monitor the utilization of the Issue Proceeds in accordance with the applicable provisions of the SEBI ICDR Regulations."

6 In the Notice, page no. 16, in Sr. No. 4 (Relevant Date), the following text is inserted at the end of the existing para, "The Relevant Date is August 31, 2026."

7 In the Notice, page no. 16, in Sr. No. 5 (Basis or justification for the price (including the premium, if any), the 2nd and 3rd para is replaced with the following paras due to change in calculation of floor and issue price, as per pricing formula as per the SEBI ICDR Regulations.

"The floor price for the Equity Shares is Rs. 403.82, as per the pricing formula prescribed under the SEBI ICDR Regulations for the Preferential Issue and is the highest of the following.

a) 90 trading days volume weighted average price of the equity shares of the Company preceding the Relevant Date, ie Rs. 384.09 per equity share.

b) 10 trading days volume weighted average price of the equity shares of the Company preceding the Relevant Date, ie Rs. 403.82 per equity share.

The Issue Price cannot be less than the floor price as mentioned above. It has approved the issue price of Rs. 404/- per Equity Share (including premium of Rs. 403 per share), being not less than the floor price computed in accordance with Chapter V / applicable provisions of the SEBI ICDR Regulations."

8 In the Notice, page no. 16, in Sr. No. 6 (The amount which the Company intends to raise by way of such securities), the amount is substituted by the amount as Rs. 335,00,00,724.

9 In the Notice, page no. 17, in Sr. No. 9 in first para, the amount should be read as Rs. 335,00,00,724, and in the second para the number of shares be read as 82,92,081.

10 In the Notice, page no. 17, in Sr. No. 10, the first para is replaced with the following texts with name of the promoter group allottee.

"Pharmaceutical Business Group (India) Limited, a promoter group entity is intended to subscribe to Equity Shares as mentioned in the resolution and the Statement."

11 In the Notice, page no. 17, in Sr. No. 11 (Shareholding pattern of the issuer before and after preferential issue), the table is replaced with the following table with updated post shareholding.

Sr. No.	Category of Shareholder(s)	Pre Issue		Post Issue	
		No. of shares held	% of share holding	No. of shares held	% of share holding
A	Promoters & Promoter Group Holding				
1	Indian				
a)	Individual	37,26,796	2.86	37,26,796	2.69
b)	Bodies Corporate	7,34,91,287	56.47	7,96,79,408	57.55
c)	Others	0	0.00	0	0.00
	Sub Total (A)(1)	7,72,18,083	59.33	8,34,06,204	60.25
2	Foreign	0	0.00	0	0.00
	Sub Total (A)(2)	0	0.00	0	0.00
	Total Promoters & Promoter Group Holding(A)	7,72,18,083	59.33	8,34,06,204	60.25
B	Non-Promoters Holding				
1	Institutional Investors	2,43,66,325	18.72	2,62,22,759	18.94
	Sub-Total (B)(1)	2,43,66,325	18.72	2,62,22,759	18.94
2	Non-Institutions				
a)	Private corporate bodies	35,82,331	2.75	35,82,331	2.59
b)	Directors and relatives	1,69,770	0.13	1,69,770	0.12
c)	Indian public	2,13,82,088	16.43	2,13,82,088	15.44
d)	others (including NRIs)	13,42,597	1.03	15,90,123	1.15
e)	Foreign company / bank	0	0.00	0	0.00
f)	Govt/Central Govt Company	750	0.00	750	0.00
g)	Other (clearing members, HUF, Trust, IEPF etc)	20,89,761	1.61	20,89,761	1.51
	Sub-Total (B)(2)	2,85,67,297	21.95	2,88,14,823	20.81
	Total Public Shareholding (B)	5,29,33,622	40.67	5,50,37,582	39.75
	Total (A)+(B)	13,01,51,705	100.00	13,84,43,786	100.00

12 In the Notice, page no. 20, in Sr. No. 16, the table is replaced with the following table with updated post allotment holding of proposed allottees.

No.	Name of proposed allottees	Pre-allotment holding		Post-allotment holding	
		No. of equity shares	%	No. of equity shares	%
1	Pharmaceutical Business Group (India) Limited	5,07,16,440	38.97	5,69,04,561	41.08
2	Yusuf Khwaja Hamied	Nil	Nil	2,47,526	0.18
3	Special Situation India Fund	Nil	Nil	4,64,108	0.34
4	India Special Assets Fund III	Nil	Nil	6,90,594	0.50
5	ISAF III Onshore Fund	Nil	Nil	7,01,732	0.51

Wherever the number of total Equity Shares and amounts appears in the Resolution, explanatory statement and disclosures, shall be read as 82,92,081 and Rs. 335,00,00,724 respectively and issue price as Rs. 404 per share. There is no material changes. The change mainly in number of shares is due to rectifying error in floor price calculation and the same is considered in the interest of the Company.

The Corrigendum shall be circulated to the Members through electronic means in the same manner as the AGM Notice and shall also be made available on the websites of the Stock Exchanges and the Company.

All other details as mentioned in the AGM Notice, save and except as amended by this Corrigendum, shall remain unchanged. This Corrigendum shall form an integral part of the AGM Notice. The AGM Notice including Resolutions and explanatory statements shall be read in conjunction with this Corrigendum.

For the sake of utmost clarity and better understanding, the Amendments as mentioned in this Corrigendum are being updated / incorporated in the AGM Notice and the same is made available on website of the Company www.gtbl.in

Thanking you

For Gujarat Themis Biosyn Limited

Sd/-
Vineet Gawankar
Company Secretary & Compliance Officer

Date: September 21, 2026
Place: Mumbai